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Background and Objectives: To assess the improve-
ment on pelvic floor distress (PFD)‐related urogenital
symptoms using validated questionnaires after intrava-
ginal CO2 laser treatment.
Study Design/Materials and Methods: Forty postme-
nopausal women with genitourinary symptoms of
menopause (GSM) were enrolled into this prospective
cohort study and underwent vaginal laser treatment
using MonaLisa Touch® fractional CO2 laser system.
Patients received three vaginal laser treatments with
360° probe 4 weeks apart. A three‐component Pelvic
Floor Distress Inventory (PFDI‐20) validated question-
naire was filled out by each patient before each session
and 4 weeks after the final treatment. Wilcoxon rank
sum test was used to compare the before and after
treatment scores.
Results: Pelvic Organ Prolapse Distress Inventory
(POPDI‐6) scores were not significantly different after
the first treatment compared with baseline (mean ±
standard deviation [SD], 21 ± 18 vs. 17 ± 15, P = 0.44).
However, each subsequent treatment resulted in
further, statistically significant improvement in symp-
tom scores (14 ± 15, P = 0.03 and 13 ± 13, P = 0.01, after
the second and third treatments, respectively). Simi-
larly, Urinary Distress Inventory (UDI‐6) scores were
not significantly different after the first laser treat-
ment (mean ± SD, 36 ± 25 vs. 29 ± 23, P = 0.36). After
the second and third treatments there were significant
improvement in the standardized scores (24 ± 20,
P = 0.03 and 22 ± 21, P = 0.01). Colorectal‐Anal Dis-
tress Inventory (CRADI‐8) scores did not change
significantly after three laser treatments.
Conclusions: Three sessions of microablative fractional
CO2 vaginal laser treatment significantly improves patient
reported urinary and pelvic organ prolapse symptoms. ©
2019 The Authors. Lasers in Surgery and Medicine
Published by Wiley Periodicals, Inc.
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INTRODUCTION
Genitourinary syndrome of menopause (GSM) is the
new term for vulvovaginal atrophy (VVA) according to
the International Society for the Study of Women’s
Sexual Health and the North American Menopause
Society [1]. These genitourinary changes are a response
to the decreased level of circulating estrogen caused by
ageing. The hypoestrogenic environment leads to sig-
nificant tissue changes such as loss of collagen, elastin,
and smooth muscle in the genital/vaginal tissues
resulting in thinning of the vaginal epithelium, dimin-
ished blood flow, elasticity, and rugation [2]. Morpho-
logical changes lead to atrophic genitalias causing
irritation, itching, burning, dyspareunia, and contact
bleeding [3]. The syndrome altogether with its bother-
some symptoms affects 40–54% of postmenopausal
women and negatively influences their everyday
lives [4].
There are several treatment options for GSM, which
depend upon symptom severity. In cases of mild symptoms
or when hormone therapy is contraindicated, nonhormo-
nal over‐the‐counter (OTC) products like lubricants and
moisturizers are useful. If nonhormonal therapy does not
provide satisfactory symptom relief and the women have
no contraindications, locally applied estrogen in cream,
tablet, or a ring delivery system may be offered [5].
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Systemic hormone replacement therapy (HRT) is only
offered to patients who need treatment for other perime-
nopausal symptoms besides GSM [6].
Many women are reluctant to use hormonal products
and desire a more durable treatment than OTC products.
Most recently vaginal laser treatment was introduced as a
novel option for women with GSM. Many clinical trials
have investigated its efficacy and described the beneficial
effects of vaginal laser treatment, which include improve-
ment in subjective symptoms of GSM, vaginal health and
flora, sexual function and dyspareunia, and urinary
incontinence [7–13]. Zerbinati et al. described microscopic
ultrastructural changes of vaginal mucosa connective
tissue after fractional CO2 laser treatment. They were
able to confirm the production of new extracellular matrix
elements such as collagen, glycosaminoglycans, proteo-
glycans, and multi‐adhesive glycoproteins [14]. Cruz et al.
[15] investigated the effect of vaginal CO2 laser treatment
alone and also compared it in combination with topical
estriol cream and placebo cream versus sham laser
treatment and found that laser treatment is beneficial.
Other studies suggest that laser therapy may be valuable
as nonhormonal therapeutic modality when HRT is not
recommended [16,17]. Although the Food and Drug
Administration approved the CO2 laser and YAG laser
therapy for several dermatologic and plastic surgery
indications, it has not been approved for GSM, but several
previous studies have revealed a beneficial effect of
vaginal microablative fractional laser on GSM.
Pelvic floor dysfunction is a global term used to describe
conditions such as irritative lower urinary tract symp-
toms (LUTS) or dry form of overactive bladder (OAB),
pelvic organ prolapse (POP), anal/fecal (AI/FI) or urinary
incontinence (UI), and chronic pelvic pain. The pathogen-
esis and symptoms of these conditions are partially
overlapped with GSM [18]. The prevalence of PFD
increases by age especially after menopause as a
consequence of reduced circulating esrogen. On the basis
of epidemiological studies POP, UI, FI, and other PFD
symptoms affect approximately 32–35% of perimenopau-
sal and postmenopausal women [19,20], the same popula-
tion which frequently complains about GSM. Prior studies
have not evaluated the effects of laser treatment on pelvic
floor dysfunctions. Our hypothesis was that women
undergoing vaginal laser treatment will report improve-
ment not just in GSM but also in pelvic floor dysfunctions.
Our goal in this pilot study was to assess the effects of
vaginal laser treatment on pelvic floor dysfunctions using
validated and commonly used questionnaires.
MATERIAL AND METHODS
In this prospective cohort study, patients were enrolled
at the outpatient urogynecology clinic of the Department
of Obstetrics and Gynecology, University of Debrecen,
Hungary between March 2017 and March 2018. Enroll-
ment criteria included the presence of any of the following
symptoms in a postmenopausal woman: GSM/VVA, mild
stress, or urgency urinary incontinence (UI), feeling of
looseness of the vagina due to the lack of pelvic muscle
tone, or symptoms of low grade pelvic organ prolapse
(POP), defined as ≤Stage II prolapse according to the
pelvic organ prolapse quantification system (POP‐Q) [21].
To be considered postmenopausal, individuals had to have
at least 12 consecutive months of amenorrhea without any
other obvious reason or consistently elevated follicle‐
stimulating hormone (FSH) blood levels of 30mIU/ml or
higher. Exclusion criteria included pregnancy, hormone
therapy in the previous 2 years (local or systemic), vaginal
infection at presentation, cytological atypia, dysmenor-
rhea, POP> Stage II, severe UI, severe fecal incontinence
(FI) or any disease, which would interfere with the study
protocol. Patients were also asked to suspend the vaginal
use of any nonhormonal or other products at least six
weeks prior to intravaginal laser treatment.
At the first visit general gynecological visit, a medical
history was taken (age, body mass index, previous
deliveries or operations, menstruation cycle, onset of
menopause, hormonal therapy). Patients were asked to
complete the Pelvic Floor Distress Inventory (PFDI‐20)
questionnaire, which has three components: Pelvic Organ
Prolapse Distress Inventory 6 (POPDI‐6), Colorectal‐Anal
Distress Inventory 8 (CRADI‐8), and Urinary Distress
Inventory (UDI‐6). POPDI‐6 assesses bother from pro-
lapse, the CRADI‐8 inquires about defecatory distress,
and the UDI‐6 assesses urinary bother. Women under-
went three sessions of intravaginal microablative CO2
laser therapy 4–6 weeks apart and filled out the PFDI‐20
questionnaire at the following timepoints: “baseline”
before the first treatment; after the first treatment (right
before the second treatment); after the second treatment
(right before the third treatment); and 6 weeks after the
final, third treatment of CO2‐Laser system (SmartXi-
de2V2LR, MonaLisa Touch®; DEKA, Florence, Italy).
Demographic and pertinent clinical information was
recorded prospectively and stored in a dedicated database.
Our study was approved by the Hungarian National
Institutional Review Medical Research Council. All
women signed a written informed consent prior to
participating in our research. There were no withdrawals
or discontinuation of treatment due to adverse events.
Questionnaires
Internationally standardized questionnaires intended
to demonstrate subjective pelvic floor symptoms were
examined. Out of the several questionnaires available, we
have selected the short‐form version of the PFDI‐20.
Previously this questionnaire was found valid, reliable,
and responsive to clinically important changes [22,23].
The PFDI‐20 has three scales: POPDI‐6, CRADI‐8, and
UDI‐6. To specify the severity of pelvic floor distress
symptoms the patients find response options ranged from
0 (“no” references “no symptoms”), 1 (“not at all”
references “symptoms are present but not bothered at
all”) to 4 (“quite a bit” as in symptoms are present and
quite bothersome). To calculate the score, the mean score
of answered items within each component is multiplied by
25 to obtain the scale score (range 0–100). Summary
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scores are calculated by summing the scale scores (range
0–300). Higher scores indicate more symptom dis-
tress [22,24].
Laser Therapy
For laser treatment microablative, fractional CO2
laser system (SmartXide2V2LR; Deka) was applied,
with a specific 360° probe designed for intravaginal
procedures. Laser beams were fractionally emitted in
small points (DOT’s) around the vaginal mucosa during
treatment. To achieve the required effect, the laser was
used in D‐Pulse mode. Depth was set, laser power,
dwell time and spacing were adjusted: SmartStak
1, 30W power, 1,000 μs dwell time and 1,000 μm
spacing [25].
Statistical Analysis
The statistical analysis was performed with SigmaStat/
SPSS (SPSS Inc., Chicago, IL) software. To describe the
clinical and demographic characteristics means and
standard deviations were used for continuous variables.
Wilcoxon rank sum test (also called Mann–Whitney U
test) was used to compare the differences between the
baseline scores and scores after subsequent treatments.
Differences were considered significant when the P< 0.05.
Data are presented as mean values (± standard deviation
[SD]) if not otherwise specified.
RESULTS
Forty menopausal women with typical GSM symptoms
were enrolled into the study. The mean age was 58± 10
years. Clinical and demographical characteristics are
described in Table 1.
The summary scores of PFDI‐20 displayed no signifi-
cant improvement after the first treatment compared to
baseline scores (mean± SD score, 74± 47 at baseline vs.
57± 38 after the first treatment, P= 0.1). After the second
and third treatment we detected significantly lower
summary scores of 46± 38 (P< 0.01) and 44± 39
(P< 0.01) as it was at baseline (Table 2).
Evaluating each individual domain of this question-
naire the mean scores developed as follows:
(1) POPDI‐6 standardized scores showed no significant
difference in prolapse symptoms after the first treat-
ment (mean±SD score, 21± 18 at baseline vs. 17± 15
after the first treatment, P= 0.44). But, after the second
treatment there was a significant improvement in the
standardized score to 14± 15 (P= 0.03). Similarly,
further improvement was seen after the third treat-
ment with a mean score of 13± 13 (P= 0.01) (Table 2).
(2) UDI‐6 standardized scores describe severity of the
urinary distress symptoms. These were not signifi-
cantly different after the first laser treatment (mean±
SD score, 36± 25 vs. 29± 23 after the first treatment,
P= 0.36). However, after the second and third treat-
ments study participants had significant improve-
ment with scores of 24± 20 (P= 0.03) and 22± 21
(P= 0.01) (Table 2), respectively.
(3) CRADI‐8 standardized scores characterize the color-
ectal‐anal complaints of the participants. These
values did not change significantly after three laser
treatments (mean± SD score, 16± 16 vs. 12± 13 after
the first treatment/11 ± 12 after the second treatment/
10± 14 after the third treatment) (Table 2).
DISCUSSION
In our pilot study, we have demonstrated that vaginal
CO2 laser therapy improves urinary and prolapse symp-
toms in postmenopausal women with GSM, as measured
by their responses on the PFDI‐20.
GSM has a significant adverse impact on the integrity
and function of the pelvic floor. The decreased level of
circulating estrogen causes microstructural changes in
the vaginal and pelvic floor tissues. These changes lead to
the development of bothersome GSM symptoms such as
itching, burning, dyspareunia, or urinary distress that
negatively affect quality of life (QoL) [3]. In the last few
years, intravaginal CO2 laser was introduced as a new
nonhormonal therapeutic modality for GSM.
We focused on the symptoms of pelvic floor dysfunction
in postmenopausal women and attempted to find the best
possible combination of questionnaires available to eval-
uate the results before, during, and after three sessions of
intravaginal microablative, fractional CO2 laser treat-
ment. In our opinion the validated PFDI‐20 questionnaire
with its subquestionnaires covers broad symptoms of PFD
by including lower urinary tract and urinary incontinence
symptoms, symptoms related to prolapse, and colorectal‐
anal dysfunction or fecal incontinence.
Standardized questionnaires have been used in several
prior studies. Our study both confirms and adds to the
existing literature. Salvatore et al. treated 50 women with
intravaginal CO2 laser and utilized the Sort Form Health
Survey (SF‐12) to assess response. SF‐12 is a general QoL
questionnaire and it is not specific for pelvic floor
complaints. Another study assessed sexual function with
the FSFI questionnaire, which reflects sexual complaints
related to PFDmore accurately [7,8]. In a study from 2016,
Sokol et al. [26] analyzed PFD symptoms based on Female
Sexual Function Index (FSFI) and SF‐12 questionnaires in
30 women after intravaginal CO2 laser therapy and
reported significant improvement on sexual function.
Pitsouni et al. applied also the FSFI questionnaire to
evaluate sexual function related to this treatment. Overall
20–60% of the patients experienced improvement in their
sexual life, and specifically reported an increased number
TABLE 1. Clinical and Demographic Characteristics
Variables Mean± standard deviation
Number of women, N 40
Age (years) 58± 10
Gravida 2± 1
Para 2± 1
Body mass index (kg/m2) 26± 5
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of sexual encounters. LUTS were also measured using
International Consultation On Incontinence Question-
naire‐Female Lower Urinary Tract Symptoms and
Urinary Incontinence (ICIQ‐FLUTS and ICIQ‐UI), UDI‐6
and King’s Health Questionnaire (KHQ). The authors
found significant reduction of questionnaire scores in
almost every domain, reflecting the improvement of
urinary symptoms. This study confirms existing findings
that UDI‐6 is a reliable tool to evaluate LUTS and their
impact on quality of life after CO2 laser treatment [27].
Behnia‐Willison et al. investigated the efficacy of vaginal
CO2 laser in Australian postmenopausal women. To
evaluate favorable effect of the treatment a validated
interviewer‐administered pelvic floor questionnaire, the
Australian Pelvic Floor Questionnaire was completed by
patients. This questionnaire assesses the severity of
bladder, bowel, and sexual function bothersomeness and
also condition‐specific quality of life. However, it measures
sexual function directly and self‐administration seems to
even be more useful during everyday practice [28].
Gambacciani and Gonzalez et al. chose ICIQ‐SF ques-
tionnaire for urinary symptoms after laser treatment.
Both studies described improved quality of life as a result
of treatment, although Gambacciani et al. used a different,
erbium laser for the treatment [13,29].
Using the PFDI‐20, we confirmed and expanded
existing findings on the impact of laser therapy on pelvic
floor dysfunction. Consistent with other studies, we found
improvement in urinary symptoms. After two laser
sessions, the urinary distress (UDI‐6) domain of the
questionnaire improved significantly. We also found a
significant improvement in the prolapse related answers
(POPDI‐6) after more than one laser treatment. CRADI‐8
colorectal scores improved after every laser session, even
though the results were not statistically significant.
Jaeschke et al. [30] published the concept of the
minimal important change (MIC), which helps to deter-
mine if statistically significant changes are also clinically
important. According to this a change should be greater
than MIC to consider clinically relevant.
Barber et al. and Wiegersma et al. both investigated the
reliability of PFDI‐20 questionnaire and also defined the
MIC of the questionnaire answers in their study popula-
tion. The study of Barber et al. investigated the summary
score of PFDI‐20 after surgery due to PDF complaints.
They found that a reduction of 15% or more in the
summary score would be considered as “clinically im-
portant” [22]. Wiegersma et al. investigated the same
changes in a study population of 214 women who chose
conservative prolapse treatment and filled out the PFDI‐
20 questionnaire. According to their results, the summary
score of the PFDI‐20 should decrease by 23% or more to be
clinically relevant [31]. In our study the mean total PFD
score decreased by 23% after the first, by 38% after the
second, and by 41% after the third laser treatment
compared with the baseline scores. Taking into considera-
tion the more conservative MIC requirement of ≥23%
score decrease, after the second treatment the observed
PFD score decrease surpassed the minimum MIC and the
total score decreased even more after the third laser
treatment. Overall these results confirm that CO2 laser
treatment is useful to diminish bothersome symptoms
caused by Pelvic Floor Dysfunction.
There is very limited information in literature regard-
ing prospective cohort studies evaluating PFD symptoms
with PFDI‐20 questionnaire after vaginal microablative
CO2 laser treatment. We believe this study brings added
value to the existing literature.
The primary limitations of this study are the lack of
control group, the relatively small sample size and short
follow‐up period. Also, our study design is unable to
distinguish whether the observed improvement in PFD
bother is a direct result or simply secondary to the
improvement of GSM. To properly assess treatment
efficacy of vaginal laser treatment on PFD‐related
symptoms a randomized, sham‐controlled (laser vs. sham
laser) trial would be necessary.
CONCLUSION
In conclusion, our findings suggest that at least two
sessions of vaginal microablative CO2 laser treatment
significantly improved postmenopausal pelvic floor dys-
function‐related urinary and prolapse symptoms.
TABLE 2. The Standardized Scores of PFDI‐20, POPDI‐6, CRADI‐8, and UDI‐6 Questionnaire Before and After
First Treatment, After Second Treatment, and 6 Weeks After the Third Treatment of CO2 Vaginal Rejuvenation
Laser
CO2 laser treatment P value
Baseline After first
After
second After third
Baseline vs.
first
Baseline vs.
second
Baseline vs.
third
PFDI‐20 (mean±SD) 74± 47 57± 38 46± 38 44± 39 0.10 <0.01* <0.01*
POPDI‐6 (mean± SD) 21± 18 17± 15 14± 15 13± 13 0.44 0.03* 0.01*
CRADI‐8 (mean± SD) 16± 16 12± 13 11± 12 10± 14 0.17 0.22 0.06
UDI‐6 (mean± SD) 36± 25 29± 23 24± 20 22± 21 0.36 0.03* 0.01*
CRADI‐8, Colorectal‐Anal Distress Inventory; PFDI‐20, Pelvic Floor Distress Inventory; POPDI‐6, Pelvic Organ Prolapse Distress
Inventory; UDI‐6, Urinary Distress Inventory.
*Indicate statistically significant data (P< 0.05).
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